Respondents ages 18 to 65 highlight urgency
for medical recognition, scientifically proven interventions, and
genetic testing for personalized obesity treatment.
MENLO
PARK, Calif., Aug. 1, 2024
/PRNewswire/ -- Phenomix Sciences (Phenomix), a precision
medicine biotechnology company that brings data intelligence to the
treatment of obesity, today announces the results from a new U.S.
weight loss survey from 475 patients who have struggled with excess
weight or are currently overweight or obese. The survey provides
valuable insights into patients' evolving preferences for obesity
treatment, how they receive this information, and what that means
for the future of anti-obesity medications, like GLP-1s.
The survey findings reveal the majority of patients are
interested in treating obesity as a medical condition. Two-thirds
(66 percent) of patients surveyed prefer guidance from clinical
care providers to manage their weight loss. The survey also
highlights patients' growing desire to personalize obesity care to
their specific needs. Nearly two-thirds of patients surveyed (62
percent) are interested in learning more about their condition
through genetic testing and want an obesity intervention tailored
to their genetic findings. This data indicates strong momentum for
personalized medicine as a cornerstone in the treatment of obesity.
In addition, 53 percent of them are willing to pay for a genetic
obesity test.
"Getting expert clinical advice on managing weight loss, as
opposed to information readily consumed on social media platforms,
is vital for patients' ongoing success in their weight loss
journey," said Zaid Jabbar, M.D.,
M.S., obesity medicine physician with Duly Health and Care. "This
survey shows that patients are more likely than ever to talk with
their provider about taking control of their weight loss, and we
know that involving a healthcare provider improves treatment
adherence significantly. By offering the MyPhenome test in our
clinic, we believe we can now offer better care and positively
impact patients' perspectives on their weight loss journey,
ultimately changing the conversation with our patients for the
better."
While the patient perspective is shifting to a more clinical
mindset surrounding obesity care, respondents largely noted they
first learned about GLP-1s and weight loss medications via TV (36
percent) and social media, including TikTok (28 percent),
Instagram/Facebook (26 percent) and Twitter/X (20 percent). This is
in contrast to just 17 percent hearing about it from a healthcare
provider, showcasing a continued need for patient education and
communication surrounding clinical weight loss solutions backed by
scientific evidence.
"The results of this survey reflect a notable evolution for
obesity treatment. The new obesity medications have reinforced the
long overdue need to treat obesity as a disease and it's clear
patients welcome that change. However, as this transition
continues, it is clear, too, that there needs to be more focus on
how patients receive weight loss information and utilize available
treatments backed by scientific research," says Mark Bagnall, CEO of Phenomix Sciences.
"We've seen that there is no 'one-size-fits all' solution, even
with new and effective medications, and the average patient with
obesity is now expressing a growing curiosity about the root causes
of obesity. Our goal is to reach patients where they are, whether
that's providing the MyPhenomeTM test to
obesity medicine providers in local markets and clinics or through
telehealth platforms like Hello Alpha. These partnerships not only
enhance patient outcomes but also contribute substantially to
addressing and mitigating the global epidemic of obesity," Bagnall
said.
For more information about Phenomix Sciences, visit
phenomixsciences.com.
About Phenomix Sciences
Phenomix Sciences is a
precision obesity biotechnology company on a mission to conquer
obesity globally through the use of our proprietary genetic tests,
unique data sets and advanced analytics. Phenomix believes that the
key to understanding obesity is its unprecedented access to
clinical and molecular information throughout all stages and
phenotypes of the disease. Phenomix leverages data intelligence to
yield better accuracy in predicting individual patient response to
specific weight loss interventions and reducing the variability in
weight loss results for patients. For more information, please
visit www.phenomixsciences.com.
Media Contact:
phenomix@ampublicrelations.com
View original
content:https://www.prnewswire.com/news-releases/new-survey-shows-strong-patient-support-for-personalized-obesity-interventions-302212282.html
SOURCE Phenomix Sciences